Cerebrolysin
Cerebrolysin (Porcine Brain-Derived Neuropeptide Preparation)
Neurotrophic Peptide Preparation for Cognitive Enhancement
What is Cerebrolysin?
Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue through a controlled enzymatic hydrolysis process. The resulting compound is a mixture of low-molecular-weight peptide fragments and free amino acids, the most therapeutically significant of which can cross the blood-brain barrier. This capacity for central nervous system penetration distinguishes Cerebrolysin from many other neurological compounds and is central to its proposed mechanism of action.
The peptide mixture is believed to mimic the activity of endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF). These proteins regulate neuronal survival, synaptic plasticity, and the growth and maintenance of neurons throughout the brain. Because the peptide fragments in Cerebrolysin are small enough to cross the blood-brain barrier where full-sized growth factors cannot, researchers have investigated whether Cerebrolysin can effectively deliver neurotrophic signaling to the central nervous system.
Preclinical and clinical research has examined Cerebrolysin in the context of stroke recovery, traumatic brain injury (TBI), Alzheimer's disease, and general cognitive aging. A meta-analysis pooling six randomized, double-blind, placebo-controlled trials in mild-to-moderate Alzheimer's disease found Cerebrolysin was significantly more effective than placebo for cognitive function at four weeks, with effect sizes comparable to approved cholinesterase inhibitors. Research published in 2025 further explored its role in modulating secondary injury mechanisms following TBI, with investigators noting its potential to support neuronal survival and functional recovery.
Despite these findings, Cerebrolysin remains non-approved in the United States. A 2013 Cochrane review rated the overall evidence quality as very low, citing small sample sizes, short follow-up periods, high risk of bias, and predominantly manufacturer-funded studies. It is currently approved in a number of European and Asian countries for neurological indications. Researchers and clinicians working with Cerebrolysin in the United States treat it strictly as a research compound outside of any approved therapeutic context.
Research Supply
Source high-purity Cerebrolysin for your research
Dosage Guide
Route: Intravenous (IV) infusion (primary) or intramuscular (IM) injection
Dosing Schedule
| Period | Dose |
|---|---|
| Cognitive support (low) | 5 mL (215 mg) daily for 10 days |
| Neurological recovery (moderate) | 10-20 mL daily for 20-28 days |
| Clinical trial dose (Alzheimer's) | 30 mL daily IV infusion for 4 weeks |
| Maintenance cycle | 5-10 mL daily for 5-10 days, 1-3x per year |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 5 mL (215 mg) | 5 mL IM or diluted IV | Low cognitive support dose |
| 10 mL (430 mg) | Dilute in normal saline for IV | Moderate neurological dose |
| 30 mL (1290 mg) | Dilute in normal saline for IV | Clinical trial dose (Alzheimer's) |
Administration Tips
- Cerebrolysin should not be self-administered without medical supervision
- IV preparation and administration requires sterile technique and clinical oversight
- Administer IV infusion slowly over 20-60 minutes to minimize side effects
- Cycles of 10-20 daily injections followed by a rest period are the most common clinical approach
- For cognitive support in non-pathological settings, use 5-10 mL in cycles of 10 days, repeated 1-3x per year
- Higher doses (30 mL/day) do not consistently outperform moderate doses and may carry higher side effect burden
Risks & Side Effects
Commonly Reported
Serious Risks
Allergic or anaphylactic reactions
Cerebrolysin is derived from animal tissue and carries a risk of hypersensitivity reactions. Reactions may range from mild urticaria to anaphylaxis. Emergency treatment should be immediately available during administration.
Seizures
Rare reports of seizure activity exist, particularly in individuals with pre-existing seizure disorders.
Severe hypotension
Rapid IV infusion has been associated with significant drops in blood pressure.
Contraindications
- Known allergy to pork or porcine-derived products
- Epilepsy or active seizure disorders (use with extreme caution)
- Renal failure (excretion may be impaired)
- Pregnancy and breastfeeding (safety not established)
- Active psychosis or acute psychiatric disturbance
- Concurrent use with MAO inhibitors or antidepressants (additive CNS effects possible)
Frequently Asked Questions
Related Peptides
Experts Covering Cerebrolysin
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Cerebrolysin has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.